Clinical trial • Phase I • Immunology
ABO21009 for Rheumatoid arthritis
Phase I trial of ABO21009 for Rheumatoid arthritis. Placebo-controlled. 78 participants.
Overview
- Trial Therapeutic Area
- Immunology
- Trial Disease
- Rheumatoid arthritis
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 16-12-2024
- First CTIS Authorization Date
- 31-01-2025
Trial design
Placebo-controlled Phase I trial across 4 sites in Netherlands, Belgium, Germany.
- Comparator
- Placebo
- Target Sample Size
- 78
Recruitment
- Planned Sample Size
- 78
- Recruitment Window Months
- 31
Geography
- Total Number Of Sites
- 4
- Total Number Of Participants
- 78
Netherlands
- Earliest CTIS Part Ii Submission Date
- 30-01-2025
- Latest Decision Or Authorization Date
- 31-01-2025
- Processing Time Days
- 1
- Number Of Sites
- 1
- Number Of Participants
- 60
Sites
- Site Name
- Centre for Human Drug Research
- Department Name
- Immunology
- Contact Person Name
- Matthijs Moerland
- Contact Person Email
- clintrials@chdr.nl
Belgium
- Earliest CTIS Part Ii Submission Date
- 25-07-2025
- Latest Decision Or Authorization Date
- 14-08-2025
- Processing Time Days
- 20
- Number Of Sites
- 1
- Number Of Participants
- 10
Sites
- Site Name
- Centre hospitalier universitaire de Liege
- Department Name
- rheumatology
- Contact Person Name
- Clio Ribbens
- Contact Person Email
- clio.ribbens@chuliege.be
Germany
- Earliest CTIS Part Ii Submission Date
- 23-02-2026
- Latest Decision Or Authorization Date
- 10-03-2026
- Processing Time Days
- 15
- Number Of Sites
- 2
- Number Of Participants
- 8
Sites
- Site Name
- Fraunhofer Institute For Translational Medicine And Pharmacology ITMP
- Department Name
- Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP
- Contact Person Name
- Frank Behrens
- Contact Person Email
- frank.behrens@itmp.fraunhofer.de
- Site Name
- Universitaetsklinikum Erlangen AöR
- Department Name
- Department of Medicine 3 – Rheumatology and Immunology
- Contact Person Name
- Georg Schett
- Contact Person Email
- Georg.Schett@uk-erlangen.de
Sponsor
Primary sponsor
- Full Name
- Aboleris Holdco
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Belgium
Investigational products
- Investigational Product Name
- ABO21009
Related trials
Other published trials that may interest you.